[go: up one dir, main page]

MX2009006313A - Antagonistas v3 para el tratamiento o prevencion de dolor cronico. - Google Patents

Antagonistas v3 para el tratamiento o prevencion de dolor cronico.

Info

Publication number
MX2009006313A
MX2009006313A MX2009006313A MX2009006313A MX2009006313A MX 2009006313 A MX2009006313 A MX 2009006313A MX 2009006313 A MX2009006313 A MX 2009006313A MX 2009006313 A MX2009006313 A MX 2009006313A MX 2009006313 A MX2009006313 A MX 2009006313A
Authority
MX
Mexico
Prior art keywords
treatment
antagonists
prevention
chronic pain
pain
Prior art date
Application number
MX2009006313A
Other languages
English (en)
Inventor
Inga Neumann
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2009006313A publication Critical patent/MX2009006313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con un antagonista V3 para su uso en el tratamiento de dolor crónico, en particular dolor neuropático.
MX2009006313A 2006-12-13 2007-12-13 Antagonistas v3 para el tratamiento o prevencion de dolor cronico. MX2009006313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126003 2006-12-13
PCT/EP2007/063913 WO2008071779A1 (en) 2006-12-13 2007-12-13 V3 antagonists for the treatment or prevention of chronic pain

Publications (1)

Publication Number Publication Date
MX2009006313A true MX2009006313A (es) 2009-06-23

Family

ID=37654964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006313A MX2009006313A (es) 2006-12-13 2007-12-13 Antagonistas v3 para el tratamiento o prevencion de dolor cronico.

Country Status (6)

Country Link
US (1) US20100179176A1 (es)
EP (1) EP2101746B1 (es)
JP (1) JP5268935B2 (es)
CA (1) CA2671891C (es)
MX (1) MX2009006313A (es)
WO (1) WO2008071779A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804114B1 (fr) * 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US7807696B2 (en) * 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
WO2006070742A1 (ja) 2004-12-27 2006-07-06 Kyoto University 麻薬性鎮痛剤の耐性形成抑制剤
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives

Also Published As

Publication number Publication date
EP2101746B1 (en) 2013-12-11
JP5268935B2 (ja) 2013-08-21
CA2671891A1 (en) 2008-06-19
WO2008071779A1 (en) 2008-06-19
JP2010513249A (ja) 2010-04-30
CA2671891C (en) 2015-05-26
EP2101746A1 (en) 2009-09-23
US20100179176A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
MY160456A (en) Benzodiazepine bromodomain inhibitor
WO2011005942A3 (en) Oligonucleotide-based compounds as inhibitors of toll-like receptors
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
MY157716A (en) Solid dosage form of olmesartan medoxomil and amlodipine
MY150600A (en) Use of opioid antagonists for treating urinary retention
ZA200807488B (en) Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
SG2014010581A (en) Attenuated pestivirus
GB2482817A (en) Novel use
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
GB0600692D0 (en) Well treatment
PL2001456T3 (pl) Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
JO2730B1 (en) Medications for the treatment of endometriosis
TW200700071A (en) Novel use
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
WO2007131041A3 (en) The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
MX2009007054A (es) Uso terapeutico novedoso para tratar leucemia.

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
GB Transfer or rights